Edgewise Therapeutics
Quarterly Financials
| Values in thousands | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
Revenue | $0 | $0 | $2,118 | $0 |
Gross Profit | -567 | -554 | 1,059 | -2,290 |
EBITDA | -42,610 | -45,959 | -39,033 | -39,830 |
EBIT | -46,513 | -39,662 | -40,432 | |
Net Income | -36,115 | -40,798 | -39,662 | -34,129 |
Net Change In Cash | 0 | 0 | 2,118 | 0 |
Free Cash Flow | -32,632 | -37,910 | -27,231 | -27,894 |
Cash | 43,404 | 49,921 | 41,666 | 44,806 |
Basic Shares | 104,940 | 95,130 | 92,414 | 93,813 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -2,290 | -1,732 | -538 | -272 |
EBITDA | -131,523 | -112,806 | -21,541 | -42,943 |
EBIT | -133,813 | -114,538 | -22,079 | -43,215 |
Net Income | -133,813 | -100,163 | -15,397 | -42,139 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Cost of Revenue | 6,427 | -89,350 | ||
Free Cash Flow | -110,340 | -97,693 | -58,181 | -34,175 |
Cash | 41,666 | 86,097 | 21,993 | 15,566 |
Basic Shares | 92,414 | 63,723 | 53,593 | 49,500 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-09-30 | $0 |
2025-06-30 | -$0.34 |
2025-03-31 | -$0.43 |
2024-12-31 | -$0.42 |
